Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: Implications for precision medicine

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2107-2115

  Wright, Gavin M ^a   Do, Hongdo ^b   Weiss, Jonathan ^b   Alam, Naveed Z ^a   Rathi, Vivek ^c   Walkiewicz, Marzena ^d   John, Thomas ^d   Russell, Prudence A ^c   Dobrovic, Alexander ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

BRAF; EGFR; High resolution melting; KRAS; Polymerase chain reaction; Tumor heterogeneity

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ALLELE; ARTICLE; BRAF GENE; CARCINOGENESIS; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; EGFR GENE; GENE MAPPING; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; KRAS GENE; LUNG ADENOCARCINOMA; METASTASIS POTENTIAL; PRECISION MEDICINE; SYSTEMS BIOLOGY; TP53 GENE; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; HUMANS; IN SITU HYBRIDIZATION; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84899554381     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1840     Document Type: Article

References (37)

1. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-504.
2. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-27.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JHM, Asamura H et al. International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
4. Jiang S-X, Yamashita K, Yamamoto M, Piao C-J, Umezawa A, Saegusa M, Yoshida T, Katagiri M, Masuda N, Hayakawa K, Okayasu I. EGFR genetic heterogeneity of non small cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 2008; 123: 2480-6.
5. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29: 2972-7.
6. Sun P-L, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee C-T, Lee J-S, Chung J-H. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012; 7: 323-30.
7. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-82.
8. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, Travis WD, Moreira AL. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010; 34: 1155-62.
9. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008; 8: 142-2.
10. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. Oncotarget 2012; 3: 546-58.
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
12. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
13. Russnes HG, Navin N, Hicks J, Borresen-Dale A-L. Insight into the heterogeneity of breast cancer through nextgeneration sequencing. J Clin Invest 2011; 121: 3810.
14. Pelosi G, Scarpa A, Manzotti M, Veronesi G, Spaggiari L, Fraggetta F, Nappi O, Benini E, Pasini F, Antonello D, Iannuci A, Maisonneuve P, Vale G. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004; 17: 538-46.
15. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumours. Lyon: IARC Press; 2004.
16. Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol 2011; 135: 783-9.
17. Newnham GM, Conron M, McLachlan S, Dobrovic A, Do H, Li J, Opeskin K, Thompson N, Wright GM, Thomas DM. Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer 2011; 11: 93.
18. Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.
19. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffman H, Weichert W. The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. J Clin Oncol 2012; 30: 1438-46.
20. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T. Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients. J Thorac Oncol 2013; 8: 461-8.
21. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao M-S. K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. Clin Lung Cancer 2006; 8: 9-9.
22. Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994; 54: 5811-5.
23. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, Yatabe Y. Disproportionate representation ofKRAS gene mutation in atypical adenomatous hyperplasia, but even distribution ofEGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol2007; 212: 287-94.
24. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol 2007; 20: 967-73.
25. Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, Kanai Y, Asamura H, Tsuchiya R, Hirohashi S. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005; 50: 1-8.
26. Li Z-H, Zheng J, Weiss LM, Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am Journal Path 1994; 144: 303.
27. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
28. Paterakos M, Watkin WG, Edgerton SM, Moore DH, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol 1999; 30: 1459-63.
29. Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol 2001; 32: 583-9.
30. Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, Ordóñez NG, Ayala AG. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18:1224-32.
31. Oh YL, Kim KR. Micropapillary variant of transitional cell carcinoma of the ureter. Pathol Int 2000; 50: 52-6.
32. Ushiku T, Matsusaka K, Iwasaki Y, Tateishi Y, Funata N, Seto Y, Fukayama M. Gastric carcinoma with invasive micropapillary pattern and its association with lymph node metastasis. Histopathology 2011; 59: 1081-9.
33. Ohtsuki Y, Kuroda N, Yunoki S, Murakami S, Mizukami Y, Okada Y, Iguchi M, Lee G-H, Furihata M. Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer. Med Mol Morphol 2013; 46: 114-21.
34. Haupt B, Ro JY, Schwartz MR, Shen SS. Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis. Mod Pathol 2007; 20: 729-33.
35. Verdú M, Román R, Calvo M, Rodón N, García B, González M, Vidal A, Puig X. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. Mod Pathol 2011; 24: 729-38.
36. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L. Selumetinib plus docetaxel for KRASmutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2012; 14: 38-47.
37. Yoo SB, Chung J-H, Lee HJ, Lee C-T, Jheon S, Sung SW. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung. J Thorac Oncol 2010; 5: 964-9.